Amgen

Overview
Activities
Financials
News

Amgen Inc. (Nasdaq: AMGN) is one of the world's leading independent biotechnology companies, focused on developing innovative human therapeutics to treat serious illnesses. Founded in 1980, Amgen harnesses advances in human genetics and molecular biology to create medicines that address unmet medical needs in areas such as oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

Amgen's key products include Prolia and Xgeva (denosumab) for bone disorders, Repatha (evolocumab) for cholesterol management, Otezla (apremilast) for inflammatory diseases, Enbrel (etanercept) for autoimmune diseases, and LUMAKRAS/LUMYKRAS (sotorasib) for lung cancer. The company has a robust pipeline of potential new medicines in development across its therapeutic focus areas.

Amgen's product portfolio includes:

  • General Medicine: Repatha, Prolia, EVENITY, Aimovig

  • Inflammation: TEZSPIRE, Otezla, Enbrel, AMJEVITA/AMGEVITA

  • Oncology: BLINCYTO, Vectibix, KYPROLIS, LUMAKRAS/LUMYKRAS, XGEVA, Nplate

  • Biosimilars: MVASI, KANJINTI

  • Rare Disease: TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS

In 2023, Amgen acquired Horizon Therapeutics for USD 27.8 billion, adding rare disease treatments to its portfolio. The company continues to invest in research and development, with over USD 4 billion spent annually on R&D in recent years. Amgen has a global presence with products sold in approximately 100 countries and regions worldwide. The company is headquartered in Thousand Oaks, California and is a component of both the Dow Jones Industrial Average and Nasdaq-100 index.

HQ Location:
One Amgen Center Drive Thousand Oaks CA USA
Founded year:
1980
Employees:
10,000+
Human Gene Editing
Human Gene Editing
Biosimilars
Biosimilars
Loading...
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.